An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

recombinant human anti-EGFR monoclonal antibody against cancers

Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.

dexamethasone 10 mg intravenous infusion for 10 minutes before the infusion of HLX07.

diphenhydramine 30 mg intravenous infusion for 10 minutes before the infusion of HLX07.

If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions.